XUXIN (HONGKONG) BIOTECHNOLOGY CO., LIMITEDHong Kong SARRemote Full Time 3 year or above Mid-Senior level Skills: Responsible for the research and preliminary demonstration work of the departmental platform R&D projects. Assist in analyzing and solving key technical issues and problems encountered during the implementation of platform R&D projects. Can act as the project leader to carry out new project (target) project research, project information preparation, technical route development, project budget planning, project stage development, research results reporting and other matters. Tracking the project (target) of the foreword information and industry hotspots, put forward new ideas and continue to optimize and develop the existing project program. Assist in the daily operation of the R&D department, and regularly train the team staff on relevant skills. Assist in the cooperation with other drug R&D departments or CRO enterprises. Report to the department head. Complete other work assigned by the company. Additional Information Job Level Mid-Senior level Publish Date07/02/2025 Job Ref. No. N/AMinimum Qualifications Doctorate or above in Medical Services / Pharmaceutical / Hospitals. Job Function Biotechnology Research & Development (R&D)Company Overview XUXIN (Hong Kong) Biotechnology Co., Limited is a wholly-owned subsidiary established in Hong Kong in 2024 by Reco RNA (Guangzhou) Biotechnology Co., Ltd. The company was founded by a team of scientists led by a Stanford University-trained Ph. D. and senior pharmaceutical executives with extensive experience in managing international and domestic pharmaceutical companies. XUXIN focuses on AI-driven innovative RNA drug development for addressing unmet clinical needs in the treatment of genetic diseases, neurological disorders, and chronic illnesses. The AI model under development will have broad applications in RNA drug design and optimization. It is applicable for optimizing key parameters such as editing efficiency, binding affinity, and off-target effects for RNA editing modules. As the platform evolves, the AI model will also incorporate gene expression profiles, genomic variants, and phenotypic data to predict therapeutic outcomes, enhance precision in RNA drug development, and streamline the RNA drug discovery process. The AI model will be sufficient to support large-scale RNA drug screening and design for a range of diseases, thus significantly reducing time-to-market for novel therapies. #J-18808-Ljbffr